Zdrowie i gospodarka · 20/01/1998

FDA Requests Comments on Proposed Standards for Unrelated Allogeneic Hematopoietic Stem/Progenitor Cell Products

The Food and Drug Administration (FDA) is seeking public input on proposed product standards for minimally manipulated hematopoietic stem/progenitor cells derived from peripheral and cord blood for unrelated allogeneic use, with the goal of ensuring their safety and effectiveness.